Viatris Inc., a global healthcare company, operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers an array of prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs) in various therapeutic areas. These areas include noncommunicable and infectious diseases, with biosimilars in oncology, immunology, endocrinology, ophthalmology, and dermatology. APIs are available for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company also provides patients with support services such as diagnostic clinics, educational seminars, and digital tools to manage health effectively. Viatris delivers its medicines in multiple forms, including oral solid doses, injectables, complex dosage forms, and APIs. These products are distributed through pharmaceutical wholesalers/distributors, retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company has several well-known brands such as Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri, to name a few. Moreover, Viatris has collaboration and licensing agreements with well-known names such as Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company is based in Canonsburg, Pennsylvania, and was founded in 1961.